

June 23, 2020

The BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai - 400 001
Scrip Code: 541540

The National Stock Exchange of India
Limited Exchange Plaza, Bandra-Kurla
Complex Sandra (E), Mumbai - 400 051
Scrip Code: SOLARA

Dear Sir/ Madam,

Subject: Regulatory updates related to Solara's Cuddalore facility

We wish to inform that the United States Food and Drug Administration (USFDA or agency) vide its letter on June 22, 2020, has informed the Company about classifying our manufacturing site at Cuddalore, Tamil Nadu as "**Official Action Indicated**"(OAI). This outcome is based on the USFDA's inspection at the site between March 2 to March 7, 2020.

While we are disappointed with this classification, we are strongly committed to collaborating with the USFDA to satisfactorily resolve the issues raised by the agency in the form 483 issued to the Company.

The reclassification of the Cuddalore site will not impact the business continuity for FY21. The Company continues to maintain its FY21 guidance both on the revenues and EBITDA. The Company is committed to providing further updates as and when it is available to us.

Thanking you,

Yours Truly,

For Solara Active Pharma Sciences Limited



S. Murali Krishna
Company Secretary

